Investors and traders are always on the hunt for new research ideas that will lead to higher income or more profits. 24/7 Wall St. reviews many fresh research calls each morning to find…
Jon OggInvestors are used to seeing many Buy ratings from Wall St. analysts, but they often overlook or do not see when these analysts give lists of stocks to sell or when…
ThinkstockBiotech pipeline news and biotech drug news continues to hit. A report from Bank of America/Merrill Lynch is highlighting four small-cap to mid-cap biotech stocks with positive prescription trends so far in 2013.…
Jon C. Ogg ThinkstockBiogen Idec Inc. (NASDAQ: BIIB) may be a half decade or so late on this move, but as the saying goes “better late than never.” The biotech and drug company is the leader in…
Jon OggThese are some of the top analyst upgrades, downgrades and initiations seen so far from Wall St. research calls this Thursday: ADTRAN Inc. (NASDAQ: ADTN) cut to Sell at UBS but raised…
Jon OggThese are some of the top analyst upgrades, downgrades and initiations seen in Wall St. research calls this Friday. Alkermes PLC (NASDAQ: ALKS) raised to Outperform as Bull of the Day…
Jon OggThese are some of the top analyst upgrades, downgrades and initiations we have seen from Wall St. research calls this Thursday. Alkermes PLC (NASDAQ: ALKS) raised to Outperform with $24 target…
Elan Corporation, plc (NYSE: ELN) may be surging on news that it is going to spin off its drug research unit, but now there is something else to consider. Elan could be getting…
Jon OggThese are some of the top analyst upgrades, downgrades and initiations seen in Wall Street research calls this Wednesday. Alcoa Inc. (NYSE: AA) Cut to Underperform at BMO Capital Markets. Alkermes,…
If there was a merger candidate which ever made sense in biotech and pharma it is Amylin Pharmaceuticals, Inc. (NASDAQ: AMLN). News from Bloomberg is out that the company has rejected an offer to…
Alkermes plc (NASDAQ: ALKS) has filed its paperwork with the Securities and Exchange Commission for the resale covering the potential future sales by a subsidiary of Elan Corporation, plc (NYSE: ELN). The…
Jon C. Ogg Amylin Pharmaceuticals, Inc. (NASDAQ: AMLN) is up 17.8% at $14.29 on word that the FDA finally gave its once-a-week diabetes drug Bydureon approval. Alkermes Inc. (NASDAQ: ALKS) is higher as it gets…
Jon OggThese are some of this Monday’s top analyst upgrades, downgrades, and initiations seen having an impact from Wall Street research. Advanced Micro Devices Inc. (NYSE: AMD) Raised to Buy at UBS.…
Jon OggThese are some of this Wednesday’s top analyst upgrades, downgrades, and initiations seen having an impact from Wall Street research calls. Alkermes, Inc. (NASDAQ: ALKS) Removed from US 1 List but…
Jon OggEach morning during the week we publish the top analyst upgrades and downgrades that we see in the market. After looking deeper through the calls individually, there are always some critical…
